Table 3.

Studies evaluating the mid- to long-term performance of bioresorbable scaffolds in below-the-knee arterial disease.

Trial (year)	Study design	Drug coating	Lesion length, mm	Limbs (n)	Lesions (n)	Primary patency, %				Limb salvage, %
						3 m	6 m	1 y	3 y	3 m	6 m	1 y	3 y
Bosiers (2005) [61, 96]	Prospective case series	Magnesium alloy	11 (2–20)	20	20	89.5	-	73.3	-	100.0	-	94.7	-
Bosiers (2009) [97]	Prospective case series	Magnesium alloy	10.6 $\pm$ 4.9	59	72	-	31.8	-	-	93.2	87.6	-	-
Stabile (2016) [99]	Retrospective registry	Biolimus	23.5 $\pm$ 9.4	30	-			93.4		-	-	96.7	-
Varcoe (2016) [63, 98]	Prospective case series	Everolimus	19.2 (5–50)	38	43	-	96.0	96.0	87.3	-	100.0	100.0	100.0
Dia (2019) [100]	Retrospective case series	Everolimus	30.9 (10–60)	31	-	-	-	96.7	-	-	-	96.8	-
Parikh (2019) [106]	Prospective case series	Sirolimus	$\le$56	30	-	-	-	88.9	-	-	-	-	-
Kum (2019) [101]	Retrospective case series	Everolimus	22.7 $\pm$ 17.2	41	53	-	95.0	86.0	-	-	93.0	85.0	-
Huizing (2021) [102]	Pooled analysis	Everolimus	21 (15–30)	121	161		97.3	91.7	86.6 (2 y)	-	-	-	-
Varcoe (2023) [103]	Prospective case series	Everolimus	43.8 $\pm$ 31.8	173	179	-	-	79.7	-	-	98.8	97.7	-
Bosiers (2023) [104, 105]	Prospective case series	Sirolimus	29.5 (5–100)	60	-	-	90	88.3	-	-	97.0	95.0	-
Brodmann (2023) [107]	Prospective case series	Sirolimus	31.9 $\pm$ 13.9	30	31	-	83.3	-	-	-	100	-	-

n, the number of people; m, month; y, year. Lesion length is represented in two ways: either as the mean value $\pm$ standard deviation (mean $\pm$ SD) or as the median value with the 25th percentile subtracted from the 75th percentile (mean (Q25–Q75)).